$13.03
-1.22[-8.56%]
At close: Apr 24
$13.03
0[0.00%]
After Hours: 4:20PM EDT
Viridian Therapeutics
(NASDAQ:VRDN)Latest News for Viridian Therapeutics Stock (NASDAQ:VRDN)
Viridian Therapeutics Stock (NASDAQ: VRDN)
Categories: All
Thursday, March 21, 2024
Wednesday, March 20, 2024
Thursday, February 29, 2024
Wednesday, February 28, 2024
- Viridian Therapeutics shares are trading higher after the company reported Q4 financial results. Wedbush maintained an Outperform rating on the stock and raised its price target from $39 to $40.Benzinga Newsdesk - Feb 28, 2024, 12:16PM
- Navigating 6 Analyst Ratings For Viridian TherapeuticsBenzinga Insights - Feb 28, 2024, 9:00AM
- Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $40Benzinga Newsdesk - Feb 28, 2024, 8:07AM
- Needham Reiterates Buy on Viridian Therapeutics, Maintains $30 Price TargetBenzinga Newsdesk - Feb 28, 2024, 7:32AM
Tuesday, February 27, 2024
Thursday, January 18, 2024
- Viridian Therapeutics shares are trading lower after the company announced pricing of a public offering of shares of common stock.Benzinga Newsdesk - Jan 18, 2024, 10:18AM
- Here's Why Viridian Therapeutics (VRDN) Stock Is MovingHenry Khederian - Jan 18, 2024, 9:51AM
- Viridian Therapeutics Prices $150M Public Offering Of 7,142,858 Common Shares At $21/ShareBenzinga Newsdesk - Jan 18, 2024, 2:14AM
Wednesday, January 17, 2024
Tuesday, December 19, 2023
Monday, December 18, 2023
- HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $37 Price TargetBenzinga Newsdesk - Dec 18, 2023, 12:20PM
- Viridian Therapeutics shares are trading higher after the company announced the selection of VRDN-003 as its lead subcutaneous program for thyroid eye disease based on data from a Phase 1 clinical study in healthy volunteers.Benzinga Newsdesk - Dec 18, 2023, 12:08PM
- ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On MondayAvi Kapoor - Dec 18, 2023, 10:57AM
- Viridian Therapeutics Announces Clinical Data In Healthy Volunteer Study And Selects VRDN-003 As Potential Subcutaneous Anti-IGF-1R Program With Extended Half-life For Development In Thyroid Eye DiseaseBenzinga Newsdesk - Dec 18, 2023, 7:14AM
Thursday, December 14, 2023
Monday, December 04, 2023
Tuesday, November 14, 2023
- Where Viridian Therapeutics Stands With AnalystsBenzinga Insights - Nov 14, 2023, 1:01PM
- RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $35 Price TargetBenzinga Newsdesk - Nov 14, 2023, 12:09PM
- JMP Securities Maintains Market Outperform on Viridian Therapeutics, Lowers Price Target to $38Benzinga Newsdesk - Nov 14, 2023, 11:33AM
Monday, November 13, 2023
Thursday, November 02, 2023
Tuesday, October 31, 2023
Monday, October 30, 2023
- Needham Maintains Buy on Viridian Therapeutics, Lowers Price Target to $30Benzinga Newsdesk - Oct 30, 2023, 3:16PM
- Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On MondayLisa Levin - Oct 30, 2023, 10:19AM
- Viridian Therapeutics Appoints Stephen Mahoney As New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs And Announces $185M Private Placement FinancingBenzinga Newsdesk - Oct 30, 2023, 8:38AM
Thursday, October 26, 2023
Wednesday, October 04, 2023
Tuesday, October 03, 2023
Thursday, September 28, 2023
Tuesday, September 26, 2023
Thursday, September 21, 2023
Wednesday, September 13, 2023
- Analyst Ratings for Viridian TherapeuticsBenzinga Insights - Sep 13, 2023, 2:00PM
- Stifel Reiterates Buy on Viridian Therapeutics, Maintains $40 Price TargetBenzinga Newsdesk - Sep 13, 2023, 10:42AM
- Wedbush Reiterates Outperform on Viridian Therapeutics, Maintains $46 Price TargetBenzinga Newsdesk - Sep 13, 2023, 9:39AM
Thursday, August 10, 2023
- Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For ThursdayLisa Levin - Aug 10, 2023, 7:53AM
- HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $37Benzinga Newsdesk - Aug 10, 2023, 6:32AM
- Needham Maintains Buy on Viridian Therapeutics, Lowers Price Target to $40Benzinga Newsdesk - Aug 10, 2023, 4:39AM
Wednesday, August 09, 2023
- JMP Securities Maintains Market Outperform on Viridian Therapeutics, Lowers Price Target to $42Benzinga Newsdesk - Aug 9, 2023, 1:07PM
- RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price TargetBenzinga Newsdesk - Aug 9, 2023, 11:49AM
- Wells Fargo Maintains Overweight on Viridian Therapeutics, Lowers Price Target to $39Benzinga Newsdesk - Aug 9, 2023, 11:26AM